Flag of the European Union EU Clinical Trials Register Help

Clinical trials for ibs

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43865   clinical trials with a EudraCT protocol, of which   7286   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    100 result(s) found for: ibs. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2018-001203-36 Sponsor Protocol Number: BHT-II-002 Start Date*: 2019-01-09
    Sponsor Name:4D Pharma Plc
    Full Title: A Phase 2 Randomised, Double Blind, Placebo Controlled, Parallel Group, Multicentre Study to Evaluate the Safety and Efficacy of Repeated Oral Doses of Blautix™ in Adult Subjects with Irritable Bow...
    Medical condition: Irritable Bowel Syndrome (IBS), subtypes IBS-C and IBS-D
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004856 10060849 Diarrhoea predominant irritable bowel syndrome LLT
    20.1 100000004856 10066868 Constipation predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-000245-12 Sponsor Protocol Number: Repha_1436 Start Date*: 2020-01-20
    Sponsor Name:Repha GmbH
    Full Title: Controlled clinical trial to evaluate the efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhea-dominant irritable bowel syndrome (IBS-D) and patients with mixed-type ir...
    Medical condition: A confirmed diagnosis of irritable bowel syndrome (IBS-D or IBS-M) by a specialist in gastroenterology and/or internal medicine and/or general medicine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10023002 Irritable bowel LLT
    26.0 10017947 - Gastrointestinal disorders 10060845 Diarrhea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-024028-24 Sponsor Protocol Number: IBS-PTX Start Date*: 2012-05-30
    Sponsor Name:Hospital Universitario de Canarias
    Full Title: EFFECT OF PENTOXIFYLLINE ON THE TIGHT JUNCTIONS (TJs) OF THE INTESTINAL MUCOSA IN PATIENTS WITH IRRITABLE BOWEL SYNDROME (IBS).
    Medical condition: IRRITABLE BOWEL SYNDROME (IBS) generates tomach pain and changes in depositions number and consistency. IBS has a high prevalence in Digestive consultations. In spite of this, we haven´t good treat...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002657-60 Sponsor Protocol Number: STO-010 Start Date*: Information not available in EudraCT
    Sponsor Name:Klinikum der Universität
    Full Title: THE EFFECT OF NEU-P11 ON SYMPTOMS IN PATIENTS WITH D-IBS
    Medical condition: Irritable Bowel Syndrome (IBS)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10021192 IBS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000214-71 Sponsor Protocol Number: NAK-03 Start Date*: 2008-07-01
    Sponsor Name:Laboratorios Menarini S.A. (Menarini Group)
    Full Title: Double blind, randomized, placebo-controlled, parallel group study to evaluate the effect of a 4-week treatment with oral doses of MEN15596 in irritable bowel syndrome.
    Medical condition: Irritable Bowel Syndrome.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023003 Irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) SK (Completed) LV (Completed) DE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000324-17 Sponsor Protocol Number: GA18/118305 Start Date*: 2019-08-02
    Sponsor Name:University of Leeds
    Full Title: Amitriptyline at Low-dose and Titrated for Irritable Bowel Syndrome as Second-line Treatment (The ATLANTIS study): A Double-blind Placebo-controlled Trial
    Medical condition: Irritable Bowel Syndrome (IBS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    20.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-002116-10 Sponsor Protocol Number: i3.1_IBS+SIBO Start Date*: 2019-09-27
    Sponsor Name:AB-Biotics S.A.
    Full Title: Interventional post-marketing study to evaluate i3.1 efficacy on SIBO (Small Intestinal Bacterial Overgrowth)reduction in IBS (Irritable bowel syndrom) patients
    Medical condition: Irritable Bowel Syndrome (IBS) + Small Intestinal Bacterial Overgrowth (SIBO)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002394-22 Sponsor Protocol Number: RFIB3053 Start Date*: 2013-09-26
    Sponsor Name:Salix Pharmaceuticals, Inc.
    Full Title: A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects with Irritable Bowel Syndrome with Diarrhoea (IBS-D)
    Medical condition: Irritable bowel syndrome (IBS) is a heterogeneous gastrointestinal (GI) disorder characterized by frequent and debilitating symptoms (e.g. diarrhoea, bloating, abdominal pain, urgency to defecate, ...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004856 10060849 Diarrhoea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020906-14 Sponsor Protocol Number: 50591903 Start Date*: 2011-03-31
    Sponsor Name:MUMC
    Full Title: Randomized controlled trial of escitalopram versus placebo for patients with irritable bowel syndrome and panic disorder.
    Medical condition: IBS and panic disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004702-14 Sponsor Protocol Number: 530079.01.302 Start Date*: 2016-04-01
    Sponsor Name:Dr. Willmar Schwabe GmbH & Co. KG
    Full Title: Efficacy and Tolerability of Menthacarin in Patients (≥ 18 years old) suffering from symptoms of Irritable Bowel Syndrome (IBS)
    Medical condition: Symptoms of Irritable Bowel Syndrome (IBS) characterized by recurrent abdominal pain, abdominal discomfort, abdominal cramping, abdominal fullness, abdominal bloating or flatulence usually accompan...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000500-16 Sponsor Protocol Number: MU0524 Start Date*: 2006-09-13
    Sponsor Name:Ardeypharm GmbH
    Full Title: E. coli Stamm Nissle 1917 zur Behandlung des postinfektiösen/Antibiotika-assoziierten Reizdarmsyndroms mit Diarrhö E. coli strain Nissle 1917 for the treatment of post-infectious/antibiotic-associ...
    Medical condition: postinfectious/antibiotic-associated Irritable Bowel Syndrome with diarrhea
    Disease: Version SOC Term Classification Code Term Level
    8.1 10060845 Diarrhea predominant irritable bowel syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000307-32 Sponsor Protocol Number: Repha_1439 Start Date*: 2020-05-12
    Sponsor Name:Repha GmbH
    Full Title: Clinical trial for examination of efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhea-dominant irritable bowel syndrom (IBS-D)
    Medical condition: Confirmed diagnosis of diarrhea-dominant irritable bowel syndrome (IBS-D) by a specialist physician and/or internal medicine and/or general medicine
    Disease: Version SOC Term Classification Code Term Level
    26.0 10017947 - Gastrointestinal disorders 10060845 Diarrhea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004977-42 Sponsor Protocol Number: CB-01-11/28 Start Date*: 2017-11-10
    Sponsor Name:Cosmo Technologies Ltd.
    Full Title: A Phase II, multicentre, randomised, double-blind, placebo controlled, proof of concept study of efficacy and safety of Rifamycin SV-MMX® 600 mg tablets administered three or two times daily to pat...
    Medical condition: Diarrhoea-predominant irritable bowel syndrome (IBS-D)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Temporarily Halted) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003418-18 Sponsor Protocol Number: SMR2268/TheMIBSStudy Start Date*: 2012-01-09
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: A Randomised, Double Blind, Placebo Controlled, Multi-centre, Parallel Group, Interventional Study of Mesalazine (Asacol®) Treatment in IBS and the Evaluation of Rectal Inflammatory Status using th...
    Medical condition: Irritable Bowel Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing) NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004626-28 Sponsor Protocol Number: SymSF2 Start Date*: 2019-07-18
    Sponsor Name:SymbioPharm GmbH
    Full Title: Randomized, double-blind, placebo-controlled, multi-centre trial to evaluate the efficacy, safety and tolerability of oral treatment with living bacteria of E. coli DSM 17252 (Symbioflor®2) in pati...
    Medical condition: Diarrhoea-predominant irritable bowel syndrome with recurrent abdominal pain according to Rome IV criteria
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2010-024177-39 Sponsor Protocol Number: RIBS-MIC/002/2010 Start Date*: 2011-02-01
    Sponsor Name:ALFA WASSERMANN
    Full Title: Prospective microbiological study on patients with non-constipation IBS treated with rifaximin 550 mg tablets.
    Medical condition: Non constipation Irritable Bowel Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060845 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-006118-17 Sponsor Protocol Number: B3I105940 Start Date*: 2006-08-17
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Crossover, Phase IIa Study to Evaluate Efficacy and Safety of the beta3-Adrenergic Receptor Agonist Solabegron in Subjects with Irritable Bowel Syndrome
    Medical condition: Irritable Bowel Syndrome (IBS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005467-16 Sponsor Protocol Number: 55995 Start Date*: 2016-06-01
    Sponsor Name:Maastricht University
    Full Title: Peppermint oil for the treatment of Irritable Bowel Syndrome: optimizing therapeutic strategies using targeted delivery
    Medical condition: Irritable Bowel Syndrome
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002550-20 Sponsor Protocol Number: AMIRA Start Date*: 2017-07-17
    Sponsor Name:University of Ulm
    Full Title: Allogeneic microbiota-reconstitution (AMR) for the Treatment of patients with diarrhea-predominant irritable bowel Syndrome (IBS-D) - the AMIRA trial
    Medical condition: diarrhea-predominant irritable bowel syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-001600-38 Sponsor Protocol Number: 27018966IBS3001 Start Date*: 2012-08-13
    Sponsor Name:Furiex Pharmaceuticals
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bow...
    Medical condition: Diarrhea-predominant irritable bowel syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10060845 Diarrhea predominant irritable bowel syndrome LLT
    20.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 27 11:23:43 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA